Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Treatment of hepatitis C virus infection in the future.

Kanda T, Yokosuka O, Omata M.

Clin Transl Med. 2013 Apr 11;2(1):9. doi: 10.1186/2001-1326-2-9.

2.

Antiviral therapies for chronic hepatitis C virus infection with cirrhosis.

Nakamoto S, Kanda T, Shirasawa H, Yokosuka O.

World J Hepatol. 2015 May 18;7(8):1133-41. doi: 10.4254/wjh.v7.i8.1133. Review.

3.

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

Asselah T, Marcellin P.

Liver Int. 2011 Jan;31 Suppl 1:68-77. doi: 10.1111/j.1478-3231.2010.02411.x. Review.

PMID:
21205141
4.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
5.

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.

Butt AA, Kanwal F.

Clin Infect Dis. 2012 Jan 1;54(1):96-104. doi: 10.1093/cid/cir774. Epub 2011 Dec 7. Review.

6.

Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives.

Chae HB, Park SM, Youn SJ.

ScientificWorldJournal. 2013 Jun 5;2013:704912. doi: 10.1155/2013/704912. Print 2013. Review.

7.

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.

Asselah T, Marcellin P.

Liver Int. 2012 Feb;32 Suppl 1:88-102. doi: 10.1111/j.1478-3231.2011.02699.x. Review.

PMID:
22212578
8.

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group.

N Engl J Med. 2004 Jul 29;351(5):438-50.

9.
10.

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team.

N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.

11.

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.

Pawlotsky JM.

Hepatology. 2011 May;53(5):1742-51. doi: 10.1002/hep.24262. Review.

PMID:
21374691
12.

Therapeutic vaccines against hepatitis C virus.

Xue J, Zhu H, Chen Z.

Infect Genet Evol. 2014 Mar;22:120-9. doi: 10.1016/j.meegid.2014.01.008. Epub 2014 Jan 23. Review.

PMID:
24462908
13.

[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].

Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y, Bruck R, Lurei Y, Kaspa RT, Abu-Mouch S, Shouval D, Ben-Ari Z; Israeli Association for the Study of the Liver.

Harefuah. 2012 Dec;151(12):709-14, 719. Hebrew.

PMID:
23330266
14.

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.

Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1.

15.

Telaprevir for previously treated chronic HCV infection.

McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM; PROVE3 Study Team.

N Engl J Med. 2010 Apr 8;362(14):1292-303. doi: 10.1056/NEJMoa0908014. Erratum in: N Engl J Med. 2010 Apr 29;362(17):1647. Dosage error in article text.

16.

[Direct antiviral treatment strategies in chronic hepatitis C].

Neumann-Haefelin C, Blum HE, Thimme R.

Dtsch Med Wochenschr. 2012 Jun;137(25-26):1360-5. doi: 10.1055/s-0032-1305064. Epub 2012 May 31. Review. German.

PMID:
22653493
17.
18.

Antiviral strategies in hepatitis C virus infection.

Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.

J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. Review.

PMID:
22300469
19.

Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Papastergiou V, Karatapanis S.

World J Clin Cases. 2015 Mar 16;3(3):210-20. doi: 10.12998/wjcc.v3.i3.210. Review.

20.

Chronic hepatitis C: treatments of the future.

Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P.

Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S84-95. doi: 10.1016/S2210-7401(11)70013-4.

PMID:
22248700
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk